Tissue factor pathway inhibitor-2 induced hepatocellular carcinoma cell differentiation

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern with limited treatment options.
• Cancer stem cells (CSCs) play a crucial role in HCC development, progression, and therapeutic resistance.
• Tissue factor pathway inhibitor-2 (TFPI-2) has shown potential anti-cancer properties in various studies.

Purpose of the Study:

• To investigate the effect of TFPI-2 over-expression on the differentiation of HCC cells (Hep3B and HepG2).
• To evaluate TFPI-2's impact on HCC cell proliferation, apoptosis, and CSC markers.
• To explore TFPI-2 as a potential therapeutic agent for HCC.

Main Methods:

• Construction of a TFPI-2 recombinant adenovirus (pAd-TFPI-2) using the pAdeasy-1 vector system.
• CCK-8 assay to assess cell proliferation.
• Flow cytometry to detect apoptosis and CD133 expression (a CSC marker).
• Real-time PCR and Western blot to analyze CSC and hepatocyte marker expression.

Main Results:

• TFPI-2 over-expression significantly suppressed HCC cell proliferation.
• TFPI-2 induced apoptosis in HCC cells.
• A dramatic decrease in CD133-positive cells (CSCs) was observed.
• Expression of CSC markers was markedly reduced, while hepatocyte markers were significantly increased in pAd-TFPI-2 infected cells (P < 0.05).

Conclusions:

• TFPI-2 over-expression induces the differentiation of hepatocellular carcinoma cells into hepatocytes.
• TFPI-2 effectively reduces HCC cell proliferation and CSC characteristics.
• TFPI-2 holds promise as a novel therapeutic strategy for hepatocellular carcinoma treatment.